Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT Code Change Applications May 2021 CPT® Editorial Panel Meeting

Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT Code Change Applications (CCAs) that have been submitted for consideration by the CPT Editorial Panel at its May 2021 meeting are listed below. These applications will also be included in the proposed Panel agenda that will be posted to the AMA website on March 12, 2021. This listing includes the code application names, code(s) affected, and a description of the request. **Until such time as the CPT Editorial Panel acts on these requests, the following information is provided for informational purposes only, giving interested individuals the information to help determine whether or not to attend the meeting and provide comment on a given topic(s).**

This listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP applications is being posted ahead of the full October Panel meeting agenda in order to provide the Molecular Pathology Advisory Group (MPAG) and the Pathology Coding Caucus (PCC) sufficient time to review comments from interested stakeholders prior to making their recommendations to the CPT Editorial Panel.

Codes that contain an 'X' (e.g., 10X24, 23X42, 03X01T) below are temporary codes that are intended to give readers an idea of the proposed placement in the code set of the potential code changes. **These temporary codes are not used for claims reporting and will be removed and not retained when the final CPT Datafiles are distributed on August 31st of each year. To report the services described by the "X" codes listed on this form, please refer to the actual codes as they appear in the CPT Datafiles publication distributed on August 31st of the corresponding year.**

Upon review of these applications, if the reviewer believes that they will need to provide comment on an issue, they should send a request for a copy of the application and associated materials to Michael Pellegrino. This request for review of the agenda materials should contain the identity of the interested party seeking such and a brief summary of the basis for the request (e.g., associated vendor/ industry representative).

Any interested parties wishing to provide written comments on any agenda items should be aware of the following relevant deadlines for provision of written comments on the agenda to ensure comment review by all parties. Additional verbal comments on any issue can be provided in person at the Panel meeting following a statement of conflict of interest. The applicant(s) who submitted the original code change application is automatically considered an interested party and is notified by AMA staff of any request for review submitted by another party.

*Interested party requests will not be processed until the interested party submits a signed confidentiality agreement and disclosure of interest form.

Updated March 10,2021

● New
▲ Revision
✚ Add on
D Deletion

Please follow the instructions in the correspondence that accompanies the materials.

Pathology/Laboratory and Molecular Pathology, Multianalyte Assays with Algorithmic Analyses, and Genomic Sequencing Procedures Deadlines for Interested Stakeholders	
Request for Code Change Application Materials	**March 15, 2021**
Submission of Written Comments	**March 22, 2021**

During the time between now and the Panel meeting, this listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP CCAs may be modified to reflect changes – additions, deletions or updates. Please check back frequently for the most up to date information. Outcomes on these actions will be listed in the CPT Editorial Panel Summary of Actions for the May 2021 meeting, which will be published on or before June 7, 2021 to the CPT home page of the AMA website http://www.ama-assn.org/go/panel-actions.

Name	Code #	Request-Description
Hydroxychloroquine Therapeutic Drug Assay	● 801XX	Add Category I code 801XX to report Hydroxychloroquine
Pancreatic Elastase Quantitative Test	▲82656 ● 826X0	Revise code 82656 to be a parent code and add a child code 826X0 to report quantitative pancreatic elastase

● New
▲ Revision
✚ Add on
D Deletion

Name	Code #	Request-Description
Mitochondrial Antibody	● 863X4	Add Category I code 863X4 for mitochondrial (antimitochondrial, AMA) antibody(ies) testing
Voltage-Gated Calcium Channel Antibody	● 865X0	Request to add Category I code 865X0 for testing of voltage gated calcium channel antibodies to diagnose autoimmune response against neurological cancer
Actin Smooth Muscle Antibody (ASMA)	● 86X02	Request to establish 86X02 to report Actin (Smooth Muscle) Antibody (ASMA) testing to diagnose autoimmune hepatitis, chronic active hepatitis, and primary biliary cholangitis
Antineutrophil cytoplasmic antibodies (ANCA)	● 86X00	Add a Category I code 86X00 to report Antineutrophil cytoplasmic antibodies (ANCA)
Blood Culture Identification PCR MultiPlex Panel	● 87X00	Add Category I code 87X00 to report infectious agent antigen detection for blood stream pathogens, including multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 26 or greater targets
Drug Interaction Assay	● 80X00	Add a new heading within the Drug Assay subsection with new guidelines and a Category I code 80X00 to report detection of interacting medications
Tier 1-Constitutional Cytogenomics-Revise 81228 81229	▲81228 ▲81229	Revise codes 81228, 81229 to conform to CPT code convention for molecular testing procedures and allow the methodology to be included within any child/offspring codes
GSP-Inherited Bone Marrow Failure Syndromes (IBMFS)	● 814XX	Add code 814XX to report the inherited bone marrow failure syndromes (IBMFS) sequence analysis panel
Admin MAAA-Renal Allograft Rejection Risk	● 002XM	Add an Administrative Multianalyte Assays with Algorithmic Analyses (MAAA) code (002XM) to report Transplantation medicine (allograft rejection, renal), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells
Cytogenomic Constitutional Analysis Low Pass Sequencing	● 812X0	Add 812X0 to report cytogenomic constitutional (genome wide) analysis via interrogation of genomic regions for copy number and loss-of-heterozygosity variants, low-pass sequencing method

Updated March 10,2021

● New
▲ Revision
✚ Add on
D Deletion